Phase 2 trial in 53 patients with new-onset or relapsing giant cell arteritis on tapering glucocorticoids: guselkumab did not improve glucocorticoid-free remission at week 28 versus placebo (40% vs 33%, P=.64); the primary endpoint was not met.
RCTn = 53 patients
Makhzoum et al. A phase 2, randomised, placebo-controlled study of guselkumab in adults with new-onset or relapsing giant cell arteritis